The FDA recently announced the approval of rilzabrutinib tablets for adults with persistent or chronic immune thrombocytopenia who did not respond to immunoglobulins, anti-D therapy, or corticosteroids.
...
Two-year data from the long-term phase 3 ALLEGRO-LT study suggest ritlecitinib maintains long-term clinical efficacy with a manageable safety profile in patients with moderate to severe alopecia areata.
...
A phase 3 trial shows that adding voclosporin to mycophenolate mofetil and low-dose glucocorticoids leads to higher rates of complete renal response and faster reduction in proteinuria for patients with...
Post hoc analyses of the phase 2 NOBILITY trial reveal that adding obinutuzumab to standard lupus nephritis therapy enhances kidney preservation and reduces glucocorticoid reliance.
In a multicenter, retrospective study, researchers evaluated time from NMOSD onset to serological diagnosis and factors associated with predicting shorter time to diagnosis.
A systematic review and meta-analysis examined the clinical differences between adult patients with neuromyelitis optica spectrum disorders and those with multiple sclerosis.
Using data from the Fibrotic Liver Disease Consortium, authors of a new study evaluated ursodeoxycholic acid’s impact on patients with primary biliary cholangitis and whether the effects differ across...
In a post hoc analysis of the ALLEGRO-2b/3 trial, investigators evaluated whether patients with alopecia areata who achieved clinically meaningful scalp hair regrowth experienced parallel improvements in...
Researchers found that approximately 1 in 7 patients with aquaporin-4 antibody positive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD) experienced neurologic symptoms before their first attack.
...
